5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Clinical O
Worsening/Suicide O
Risk O
: O
Monitor O
for O
clinical O
worsening O
, O
suicidality O
and O
unusual O
change O
in O
behavior O
, O
especially O
, O
during O
the O
initial O
few O
months O
of O
therapy O
or O
at O
times O
of O
dose O
changes O
( O
5.1 O
) O
. O

* O
Serotonin O
Syndrome O
: O
Serotonin O
syndrome O
has O
been O
reported O
with O
SSRIs O
and O
SNRIs O
, O
including O
Lexapro O
, O
both O
when O
taken O
alone O
, O
but O
especially O
when O
co-administered O
with O
other O
serotonergic O
agents O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
Wort O
) O
. O

If O
such O
symptoms O
occur O
, O
discontinue O
Lexapro O
and O
initiate O
supportive O
treatment O
. O

If O
concomitant O
use O
of O
Lexapro O
with O
other O
serotonergic O
drugs O
is O
clinically O
warranted O
, O
patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin O
syndrome O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
( O
5.2 O
) O
. O

* O
Discontinuation O
of O
Treatment O
with O
Lexapro O
: O
A O
gradual O
reduction O
in O
dose O
rather O
than O
abrupt O
cessation O
is O
recommended O
whenever O
possible O
( O
5.3 O
) O
. O

* O
Seizures O
: O
Prescribe O
with O
care O
in O
patients O
with O
a O
history O
of O
seizure O
( O
5.4 O
) O
. O

* O
Activation O
of O
Mania/Hypomania O
: O
Use O
cautiously O
in O
patients O
with O
a O
history O
of O
mania O
( O
5.5 O
) O
. O

* O
Hyponatremia O
: O
Can O
occur O
in O
association O
with O
SIADH O
( O
5.6 O
) O
. O

* O
Abnormal O
Bleeding O
: O
Use O
caution O
in O
concomitant O
use O
with O
NSAIDs O
, O
aspirin O
, O
warfarin O
or O
other O
drugs O
that O
affect O
coagulation O
( O
5.7 O
) O
. O

* O
Interference O
with O
Cognitive O
and O
Motor O
Performance O
: O
Use O
caution O
when O
operating O
machinery O
( O
5.8 O
) O
. O

* O
Angle O
Closure O
Glaucoma O
: O
Angle O
closure O
glaucoma O
has O
occurred O
in O
patients O
with O
untreated O
anatomically O
narrow O
angles O
treated O
with O
antidepressants O
. O

( O
5.9 O
) O
* O
Use O
in O
Patients O
with O
Concomitant O
Illness O
: O
Use O
caution O
in O
patients O
with O
diseases O
or O
conditions O
that O
produce O
altered O
metabolism O
or O
hemodynamic O
responses O
( O
5.10 O
) O
. O

5.1 O
Clinical O
Worsening O
and O
Suicide O
Risk O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
vs O
. O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

TABLE O
1 O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1000 O
Patients O
Treated O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening B-NonOSE_AE
depression I-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

If O
the O
decision O
has O
been O
made O
to O
discontinue O
treatment O
, O
medication O
should O
be O
tapered O
, O
as O
rapidly O
as O
is O
feasible O
, O
but O
with O
recognition O
that O
abrupt O
discontinuation B-NonOSE_AE
can I-NonOSE_AE
be I-NonOSE_AE
associated I-NonOSE_AE
with I-NonOSE_AE
certain I-NonOSE_AE
symptoms I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
health O
care O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
[ O
see O
also O
Patient O
Counseling O
Information O
( O
17.1 O
) O
] O
. O

Prescriptions O
for O
Lexapro O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar O
Disorder O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
trials O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in O
patients O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-Not_AE_Candidate
history O
, O
including O
a O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
suicide I-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

It O
should O
be O
noted O
that O
Lexapro O
is O
not O
approved O
for O
use O
in O
treating O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
. O

5.2 O
Serotonin O
Syndrome O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
Lexapro O
, O
alone O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
Wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
in O
particular O
, O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
also O
others O
, O
such O
as O
linezolid O
and O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
Lexapro O
with O
MAOIs O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
is O
contraindicated O
. O

Lexapro O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
Lexapro O
. O

Lexapro O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
[ O
see O
Contraindications O
( O
4.1 O
) O
and O
Dosage O
and O
Administration O
( O
2.5 O
and O
2.6 O
) O
] O
. O

If O
concomitant O
use O
of O
Lexapro O
with O
other O
serotonergic O
drugs O
including O
, O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
, O
amphetamine O
and O
St O
. O
John O
's O
Wort O
is O
clinically O
warranted O
, O
patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
Lexapro O
and O
any O
concomitant O
serotonergic O
agents O
, O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

5.3 O
Discontinuation O
of O
Treatment O
with O
Lexapro O
During O
marketing O
of O
Lexapro O
and O
other O
SSRIs O
and O
SNRIs O
( O
serotonin O
and O
norepinephrine O
reuptake O
inhibitors O
) O
, O
there O
have O
been O
spontaneous O
reports O
of O
adverse B-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurring I-OSE_Labeled_AE
upon I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of O
these O
drugs O
, O
particularly O
when O
abrupt O
, O
including O
the O
following O
: O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesias B-NonOSE_AE
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
and O
hypomania B-NonOSE_AE
. O

While O
these O
events O
are O
generally O
self-limiting O
, O
there O
have O
been O
reports O
of O
serious O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
. O

Patients O
should O
be O
monitored O
for O
these O
symptoms O
when O
discontinuing O
treatment O
with O
Lexapro O
. O

A O
gradual O
reduction O
in O
the O
dose O
rather O
than O
abrupt O
cessation O
is O
recommended O
whenever O
possible O
. O

If O
intolerable O
symptoms O
occur O
following O
a O
decrease O
in O
the O
dose O
or O
upon O
discontinuation O
of O
treatment O
, O
then O
resuming O
the O
previously O
prescribed O
dose O
may O
be O
considered O
. O

Subsequently O
, O
the O
physician O
may O
continue O
decreasing O
the O
dose O
but O
at O
a O
more O
gradual O
rate O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

5.4 O
Seizures O
Although O
anticonvulsant O
effects O
of O
racemic O
citalopram O
have O
been O
observed O
in O
animal O
studies O
, O
Lexapro O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

These O
patients O
were O
excluded O
from O
clinical O
studies O
during O
the O
product O
's O
premarketing O
testing O
. O

In O
clinical O
trials O
of O
Lexapro O
, O
cases O
of O
convulsion B-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
Lexapro O
treatment O
. O

Like O
other O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
Lexapro O
should O
be O
introduced O
with O
care O
in O
patients O
with O
a O
history O
of O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

5.5 O
Activation O
of O
Mania/Hypomania O
In O
placebo-controlled O
trials O
of O
Lexapro O
in O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
activation O
of O
mania B-OSE_Labeled_AE
/ O
hypomania B-OSE_Labeled_AE
was O
reported O
in O
one O
( O
0.1 O
% O
) O
of O
715 O
patients O
treated O
with O
Lexapro O
and O
in O
none O
of O
the O
592 O
patients O
treated O
with O
placebo O
. O

One O
additional O
case O
of O
hypomania B-OSE_Labeled_AE
has O
been O
reported O
in O
association O
with O
Lexapro O
treatment O
. O

Activation O
of O
mania B-OSE_Labeled_AE
/ O
hypomania B-OSE_Labeled_AE
has O
also O
been O
reported O
in O
a O
small O
proportion O
of O
patients O
with O
major B-Not_AE_Candidate
affective I-Not_AE_Candidate
disorders I-Not_AE_Candidate
treated O
with O
racemic O
citalopram O
and O
other O
marketed O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

As O
with O
all O
drugs O
effective O
in O
the O
treatment O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
Lexapro O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
. O

5.6 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
may O
occur O
as O
a O
result O
of O
treatment O
with O
SSRIs O
and O
SNRIs O
, O
including O
Lexapro O
. O

In O
many O
cases O
, O
this O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
) O
, O
and O
was O
reversible O
when O
Lexapro O
was O
discontinued O
. O

Cases O
with O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Elderly O
patients O
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-OSE_Labeled_AE
with O
SSRIs O
and O
SNRIs O
. O

Also O
, O
patients O
taking O
diuretics O
or O
who O
are O
otherwise O
volume B-Not_AE_Candidate
depleted I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
[ O
see O
Geriatric O
Use O
( O
8.5 O
) O
] O
. O

Discontinuation O
of O
Lexapro O
should O
be O
considered O
in O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
and O
appropriate O
medical O
intervention O
should O
be O
instituted O
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

5.7 O
Abnormal O
Bleeding O
SSRIs O
and O
SNRIs O
, O
including O
Lexapro O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
. O

Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
, O
warfarin O
, O
and O
other O
anticoagulants O
may O
add O
to O
the O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Bleeding B-OSE_Labeled_AE
events O
related O
to O
SSRIs O
and O
SNRIs O
use O
have O
ranged O
from O
ecchymoses B-OSE_Labeled_AE
, O
hematomas B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
petechiae B-OSE_Labeled_AE
to O
life-threatening O
hemorrhages B-OSE_Labeled_AE
. O

Patients O
should O
be O
cautioned O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
Lexapro O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
. O

5.8 O
Interference O
with O
Cognitive O
and O
Motor O
Performance O
In O
a O
study O
in O
normal O
volunteers O
, O
Lexapro O
10 O
mg/day O
did O
not O
produce O
impairment B-NonOSE_AE
of I-NonOSE_AE
intellectual I-NonOSE_AE
function I-NonOSE_AE
or O
psychomotor O
performance O
. O

Because O
any O
psychoactive O
drug O
may O
impair B-OSE_Labeled_AE
judgment O
, O
thinking O
, O
or O
motor I-OSE_Labeled_AE
skills I-OSE_Labeled_AE
, O
however O
, O
patients O
should O
be O
cautioned O
about O
operating O
hazardous O
machinery O
, O
including O
automobiles O
, O
until O
they O
are O
reasonably O
certain O
that O
Lexapro O
therapy O
does O
not O
affect O
their O
ability O
to O
engage O
in O
such O
activities O
. O

5.9 O
Angle O
Closure O
Glaucoma O
Angle O
Closure O
Glaucoma O
: O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
Lexapro O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who I-Not_AE_Candidate
does I-Not_AE_Candidate
not I-Not_AE_Candidate
have I-Not_AE_Candidate
a I-Not_AE_Candidate
patent I-Not_AE_Candidate
iridectomy I-Not_AE_Candidate
. O

5.10 O
Use O
in O
Patients O
with O
Concomitant O
Illness O
Clinical O
experience O
with O
Lexapro O
in O
patients O
with O
certain O
concomitant O
systemic O
illnesses O
is O
limited O
. O

Caution O
is O
advisable O
in O
using O
Lexapro O
in O
patients O
with O
diseases O
or O
conditions O
that O
produce O
altered B-NonOSE_AE
metabolism I-NonOSE_AE
or O
hemodynamic B-NonOSE_AE
responses I-NonOSE_AE
. O

Lexapro O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
recent O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
unstable B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Patients O
with O
these O
diagnoses O
were O
generally O
excluded O
from O
clinical O
studies O
during O
the O
product O
's O
premarketing O
testing O
. O

In O
subjects O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
clearance O
of O
racemic O
citalopram O
was O
decreased O
and O
plasma O
concentrations O
were O
increased O
. O

The O
recommended O
dose O
of O
Lexapro O
in O
hepatically B-Not_AE_Candidate
impaired I-Not_AE_Candidate
patients O
is O
10 O
mg/day O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Because O
escitalopram O
is O
extensively O
metabolized O
, O
excretion O
of O
unchanged O
drug O
in O
urine O
is O
a O
minor O
route O
of O
elimination O
. O

Until O
adequate O
numbers O
of O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
have O
been O
evaluated O
during O
chronic O
treatment O
with O
Lexapro O
, O
however O
, O
it O
should O
be O
used O
with O
caution O
in O
such O
patients O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

